

**Development, Manufacture and Sale of Diagnostic Reagents & Enzymes**  
**Nagase Diagnostics Co., Ltd. Integrated into NAGASE Group and Starts Operation**  
**in July 2025**

Nagase & Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; Representative Director, President and CEO: Hiroyuki Ueshima), with the acquisition of the diagnostic business and other areas from Asahi Kasei Pharma which was announced in September 2024, will acquire the shares of Nagase Diagnostics Co., Ltd. (Head Office: Chuo-ku, Tokyo), which operates that business, on July 1, 2025 and integrate it into the NAGASE Group.

As part of the growth strategy in its Medium-Term Management Plan ACE 2.0, Nagase & Co. Ltd. has specified the four quadrants of Foundation, Focus, Development, and Improvement, and is carrying out its businesses along the axes of the trading, manufacturing, and R&D functions. The goal of the purchase of this business and establishment of a new company is to strengthen manufacturing capabilities in the life sciences field for the Focus quadrant and expand operations in the biotechnologies field by utilizing R&D capabilities for the Development quadrant.

By using materials to solve production challenges, the NAGASE Group will contribute to bringing about a sustainable world where people live with peace of mind.

#### Profile of New Company

- Company Name (Japanese): ナガセダイアグノスティックス株式会社
- Company Name (English): Nagase Diagnostics Co., Ltd.
- Head Office: 12-15, Nihonbashi-Kobunacho, Chuo-ku, Tokyo
- Representative: Hironao Makise, Representative Director (as of July 1, 2025)
- Date of Establishment: December 3, 2024
- Commencement of Operations: July 1, 2025
- Business Summary: Development, manufacturing and sales of diagnostic kit products, diagnostic enzymes, and other life science materials
- Manufacturing Site: 632-1, Mifuku, Izunokuni-Shi, Shizuoka
- Number of Employees: 205
- Shareholder Structure: From July 1, 2025: 100% owned by Nagase & Co., Ltd. (Until June 30, 2025: 100% owned by Asahi Kasei Pharma)

#### Related Press Release

September 26, 2024

[Investment in Focus Quadrant: Life Sciences \(Manufacturing Capabilities\) Acquisition of Asahi Kasei Pharma Diagnostics Operations Expanded Sales Channels for Enzyme Manufacturing and Technological Synergy](#)

#### ◆Inquiries

Nagase & Co., Ltd. URL: <https://www.nagase.co.jp/>

<Business Inquiries> Life & Healthcare Products Dept. Tel: 090-3626-9844

<Media Inquiries>

PR Section, Corporate Relations Div., Corporate Management Dept. Tel.: 080-7740-8341